Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Biological Defense Systems (BDS) is an innovative biotechnology company specializing in the development of rapid, visual diagnostic platforms for the detection of pathogens, toxins, and chemical agents. The company's core technology utilizes polydiacetylene (PDA) nanovesicles, which are engineered to undergo a distinct colorimetric or fluorescent transition upon binding with specific biological or chemical targets. These "Bio-ID Sensors" are designed to be integrated directly into a wide range of materials, such as surgical masks, personal protective equipment, and food packaging, providing a real-time, "always-on" monitoring system that eliminates the need for traditional laboratory testing. BDS's mission is to provide inexpensive and effective early-warning systems for infectious diseases like influenza and Ebola, as well as biothreat agents like anthrax and ricin. The company is currently seeking strategic partnerships to scale its manufacturing and bring its fully developed diagnostic products to global markets.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Biological Defense Systems.